NUVECTIS PHARMA INC (NVCT) Stock Price, Forecast & Analysis
NASDAQ:NVCT • US67080T1088
NVCT Key Statistics, Chart & Performance
The current stock price of NVCT is 8.51 USD. In the past month the price decreased by -0.93%. In the past year, price increased by 27.2%.
NVCT Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to NVCT. When comparing the yearly performance of all stocks, NVCT is one of the better performing stocks in the market, outperforming 86.59% of all stocks.
NVCT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NVCT. While NVCT has a great health rating, there are worries on its profitability.
NVCT Financial Highlights
Over the last trailing twelve months NVCT reported a non-GAAP Earnings per Share(EPS) of -1.26. The EPS decreased by -8.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -78.14% | ||
| ROE | -115.81% | ||
| Debt/Equity | 0 |
NVCT Forecast & Estimates
12 analysts have analysed NVCT and the average price target is 18.53 USD. This implies a price increase of 117.74% is expected in the next year compared to the current price of 8.51.
NVCT Ownership
NVCT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.8 | 397.325B | ||
| AMGN | AMGEN INC | 16.84 | 201.795B | ||
| GILD | GILEAD SCIENCES INC | 16.8 | 187.839B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 120.999B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.94 | 82.427B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.16 | 44.414B | ||
| INSM | INSMED INC | N/A | 35.17B | ||
| NTRA | NATERA INC | N/A | 29.514B | ||
| BIIB | BIOGEN INC | 12.91 | 28.182B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.1 | 20.385B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NVCT
Company Profile
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is headquartered in Fort Lee, New Jersey and currently employs 13 full-time employees. The company went IPO on 2022-02-04. The firm is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.
Company Info
NUVECTIS PHARMA INC
1 Bridge Plaza, 2nd Floor
Fort Lee NEW JERSEY US
Employees: 13
Phone: 13608377232
NUVECTIS PHARMA INC / NVCT FAQ
What does NUVECTIS PHARMA INC do?
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is headquartered in Fort Lee, New Jersey and currently employs 13 full-time employees. The company went IPO on 2022-02-04. The firm is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.
What is the current price of NVCT stock?
The current stock price of NVCT is 8.51 USD. The price increased by 0.59% in the last trading session.
Does NUVECTIS PHARMA INC pay dividends?
NVCT does not pay a dividend.
What is the ChartMill technical and fundamental rating of NVCT stock?
NVCT has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How many employees does NUVECTIS PHARMA INC have?
NUVECTIS PHARMA INC (NVCT) currently has 13 employees.
What is the next earnings date for NVCT stock?
NUVECTIS PHARMA INC (NVCT) will report earnings on 2026-03-10, before the market open.